Results 261 to 270 of about 1,465,858 (395)

Desmoplastic melanoma in Sweden in 2009–2022: A population‐based registry study demonstrating distinctive tumour characteristics, incidence and survival trends

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The incidence of desmoplastic melanoma (DM) in Sweden remains stable, unlike rising cutaneous melanoma rates. Despite advanced tumour features, DM patients have better survival outcomes. However, recent survival improvements are lacking, potentially due to limited treatment options compared to other melanoma subtypes.
Yodit Girmay, Francesca Portelli, Rasmus Mikiver, Jan Lapins, Karolin Isaksson, Hildur Helgadottir   +5 more
wiley   +1 more source

Dermal Injection of Radioactive Colloid Is Superior to Peritumoral Injection for Breast Cancer Sentinel Lymph Node Biopsy: Results of a Multiinstitutional Study

, 2001
Kelly M. McMasters, Sandra L. Wong, Robert C.G. Martin, Celia Chao, Todd M. Tuttle, R. Dirk Noyes, David J. Carlson, Alison L. Laidley, Terre Q. McGlothin, Philip Ley, Chelsea Brown, Rebecca L. Glaser, Robert E. Pennington, Peter S. Turk, Diana Simpson, Patricia B. Cerrito, Michael J. Edwards   +16 more
openalex   +2 more sources

Switching PD‐1 to BRAF + MEK inhibition improves recurrence‐free survival in patients receiving a second course of adjuvant melanoma therapy

Journal of the European Academy of Dermatology and Venereology, EarlyView.
66 patients from 22 centers received adjuvant treatment after relapse under or after previous adjuvant therapy with BRAF + MEK or PD‐1. Data highlight a significant benefit when switching from PD‐1 to BRAF + MEK adjuvant therapy compared to a switch from BRAF + MEK to PD‐1 adjuvant regimens.
Katharina Schumann, Kai Christian Klespe, Cornelia Mauch, Carmen Loquai, Ulrike Schultheis, Sevil Börger, Alexander Thiem, Steffen Emmert, Magdalena Hoellwerth, Peter Kölblinger, Van Anh Nguyen, Marina Wanner, Erika Richtig, Wiebke K. Peitsch, Wolfgang Harth, Veronika Zenderowski, Andreas Dominik Braun, Miriam Mengoni, Reinhard Dummer, Johanna Mangana, Lara Valeska Maul, Frank Meiß, Klemens Rappersberger, Oana Diana Persa, Tilo Biedermann, Christian Posch   +25 more
wiley   +1 more source

Comparison of targeted axillary dissection with sentinel node biopsy alone on nodal recurrence for patients who have node-positive breast cancer treated with neoadjuvant chemotherapy: a critical appraisal. [PDF]

Gland Surg
Venkataraman J, Al-Shamari A, Mokbel K.
europepmc   +1 more source

What Is a False Negative Sentinel Node Biopsy: Definition, Reasons and Ways to Minimize It?

Indian Journal of Surgery, 2016
K. Kataria, A. Srivastava, Darakhshan Qaiser   +2 more
semanticscholar   +1 more source

Non‐invasive characterization of melanoma depth at single‐cell resolution

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Non‐invasive determination of Breslow depth would be beneficial for the clinical management of melanoma. We demonstrate that RSOM can achieve non‐invasive imaging of single melanocytes up to several millimetres in tissue. A pilot clinical study showed a high degree of correlation between RSOM and the standard for Breslow depth determination.
Juan Aguirre, Christine Gasteiger, Benedikt Hindelang, Markus Seeger, Andrei Bereznhoi, Ina Weidenfeld, Ulf Darsow, Andre C. Stiel, Susanne Annette Steimle‐Grauer, Christian Posch, Tilo Biedermann, Vasilis Ntziachristos   +11 more
wiley   +1 more source

Sentinel Node Mapping with Blue Dye Injection after Lumpectomy Specimen Removal: Implications for Fluorescence-Guided Breast Surgery. [PDF]

Ann Surg Oncol
Cruz HSS, Shanno JN, Webster AJ, Verdial FC, Gadd MA, Specht MC, Smith BL.   +6 more
europepmc   +1 more source

A deep learning–clinical nomogram hybrid for predicting sentinel lymph node metastasis in melanoma

Journal of the European Academy of Dermatology and Venereology, EarlyView.
We developed MISSLE, a deep learning–clinical nomogram hybrid model, to predict sentinel lymph node metastasis in invasive cutaneous melanoma with a high area under the receiver operating characteristic curve of 0.950 on the test set. MISSLE identifies key histopathological features and integrates AI for improved clinical decision‐making.
Minh‐Khang Le, Masataka Kawai, Tetsuo Kondo, Takashi Inozume, Yoshinori Muto, Youichi Ogawa, Shinji Shimada, Takashi Okamoto, Tatsuyoshi Kawamura   +8 more
wiley   +1 more source

Comparison of Targeted Axillary Dissection with Sentinel Node Biopsy Alone on Nodal Recurrence for Patients who have Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy. [PDF]

Ann Surg Oncol
Boyle MK, Amersi F, Chung A, Tseng J, Giuliano AE.   +4 more
europepmc   +1 more source

Will the sentinel lymph node (SLN) stand a second time – SLN biopsy in breast cancer patients with isolated local recurrence following breast conserving therapy and previous SLN procedure

, 2001
Janez Žgajnar, Wolfgang Gatzemeier, A. Costa   +2 more
openalex   +1 more source